13F Pro Quality Score

72.6/100

Rank #223 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

49.7/100

Profitability

89.7/100

Balance Sheet

95.1/100

Earnings Quality

46.9/100

Free Cash Flow

77.7/100

Institutional Flow

9.3/100

Revenue Scale

86.1/100

Dilution Risk

60.8/100

ZTS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Zoetis Inc. (ZTS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZTS at 72.6/100 on a 32-signal composite quality model, placing it at rank #223 of 2,879 stocks — the top 10% of the AI-ranked universe. ZTS scores in the top quartile across balance sheet strength (95.1), profitability (89.7), revenue scale (86.1). Areas of concern include institutional flow (9.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Zoetis Inc. reports quarterly revenue of $2.3B, net income of $601.0M, an operating margin of 33.5%. Top institutional holders of ZTS by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ZTS trades on the NYSE exchange and files with the SEC under CIK 1555280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zoetis Inc. directly from SEC EDGAR. Zoetis Inc.'s 13F Pro composite quality score has ranged between 8 and 81 since 2021, currently 72.6 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Fun facts about Zoetis Inc.

Quirks, history, and lore behind ZTS — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. healthcare company · large-cap · listed on the NYSE · headquartered in New Jersey.
  • 2
    The Numbers
    Annual revenue of roughly $9 billion, serving customers in more than 100 countries — not bad for an industry most humans never shop in themselves.
  • 3
    The History
    Spun off from Pfizer in 2013, it inherited decades of research and immediately became the world's largest standalone company in its niche.
  • 4
    The Secret
    Its customers are farmers, ranchers, and veterinarians — it makes medicines and vaccines not for people, but for the animals we eat and love.
  • 5
    The Lore
    Its blockbuster product Apoquel transformed treatment of itchy dogs, and its livestock portfolio covers cattle, swine, poultry, fish, and more — basically a pharmacy for the whole farm.
  • 6
    The Giveaway
    The world's largest animal health company — if your dog got a flea treatment or your steak came from a healthy cow, there's a decent chance this Pfizer spinoff had a paw in it.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.3B

Net Income

Q1 2026

$601.0M

Free Cash Flow

Q1 2026

$291.0M

Operating Margin

Q1 2026

33.5%

D/E Ratio

Q1 2026

2.80

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.3% YoY
$9.47BFY 2025
FY20 $6.67BFY22 $8.08BFY24 $9.26BFY25 $9.47B

Net Income

+7.5% YoY
$2.67BFY 2025
FY20 $1.64BFY22 $2.11BFY24 $2.49BFY25 $2.67B

EPS (Diluted)

+10.1% YoY
$6.02FY 2025
FY20 $3.42FY22 $4.49FY24 $5.47FY25 $6.02

Total Assets

+8.6% YoY
$15.47BFY 2025
FY20 $13.61BFY22 $14.93BFY24 $14.24BFY25 $15.47B

Total Debt

+37.6% YoY
$9.04BFY 2025
FY20 $7.20BFY22 $7.90BFY24 $6.57BFY25 $9.04B

Op. Cash Flow

-1.7% YoY
$2.90BFY 2025
FY20 $2.13BFY22 $1.91BFY24 $2.95BFY25 $2.90B

Get alerted when ZTS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Zoetis Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of ZTS

Put ZTS on your watchlist

Track score changes the day Zoetis Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is ZTS a good stock to buy?

13F Pro's AI-powered analysis of Zoetis Inc. (ZTS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZTS are available on the ZTS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ZTS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZTS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zoetis Inc.'s investment landscape.